Pharma BD Deal Intelligence
Endo to acquire DAVA Pharmaceuticals for $575M cash plus $25M sales-milestone earn-out, pursuing CEO De Silva's accretive M&A roll-up strategy.
Endo acquires DAVA, a specialty generics maker generating ~$131M revenue and ~$100M adjusted EBITDA in 2013, expected to be immediately accretive to…
Endo's M&A appetite continued post-DAVA with bids on Salix and Auxilium, underscoring the De Silva-era roll-up that ultimately exposed Endo to generic-pricing…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Endo agreed to acquire privately held generics maker DAVA Pharmaceuticals for $575M cash plus $25M sales-milestone earn-out. DAVA generated $131M revenue and ~$100M adj. EBITDA in 2013 across a niche specialty generics portfolio. Closed August 6, 2014.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Endo International plc / DAVA Pharmaceuticals, Inc. (this deal) | 2014 | $600M | 25 |
| Endo International plc / Auxilium Pharmaceuticals, Inc. | 2014 | $2.6B | 47 |
| Endo International plc / Grupo Farmaceutico Somar SAPI de CV | 2014 | $270M | 18 |
| Endo International plc / Par Pharmaceutical Holdings, Inc. | 2015 | $8.1B | 15 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
← Browse all deals · How we score deals
More: 2014 deals · Endo International plc deals · Other deals